04X Stock Overview
Develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Personalis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$2.33 |
| 52 Week Low | US$0.83 |
| Beta | 1.91 |
| 1 Month Change | 2.60% |
| 3 Month Change | 15.00% |
| 1 Year Change | -26.67% |
| 3 Year Change | -92.84% |
| 5 Year Change | n/a |
| Change since IPO | -93.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 04X | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 3.8% | -2.5% | -0.5% |
| 1Y | -26.7% | -13.1% | 5.2% |
Return vs Industry: 04X underperformed the German Life Sciences industry which returned -11.8% over the past year.
Return vs Market: 04X underperformed the German Market which returned 6.4% over the past year.
Price Volatility
| 04X volatility | |
|---|---|
| 04X Average Weekly Movement | 12.1% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 04X has not had significant price volatility in the past 3 months.
Volatility Over Time: 04X's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 224 | Chris Hall | www.personalis.com |
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
Personalis, Inc. Fundamentals Summary
| 04X fundamental statistics | |
|---|---|
| Market cap | €68.94m |
| Earnings (TTM) | -€85.35m |
| Revenue (TTM) | €68.34m |
0.9x
P/S Ratio-0.8x
P/E RatioIs 04X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 04X income statement (TTM) | |
|---|---|
| Revenue | US$74.15m |
| Cost of Revenue | US$55.18m |
| Gross Profit | US$18.97m |
| Other Expenses | US$111.58m |
| Earnings | -US$92.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 25.59% |
| Net Profit Margin | -124.90% |
| Debt/Equity Ratio | 2.1% |
How did 04X perform over the long term?
See historical performance and comparison